연구성과로 돌아가기
2024 연구자 정보 (43 / 1079)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Cha, Chihwan (Cha, C) |
Hanyang Univ, Coll Med, Seoul Hosp, Dept Surg, Seoul, South Korea |
AAS-4502-2021 Cha, Chihwan |
|
[JCR상위 1.7] Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06) [JCR상위 0.2] Minimal Access vs Conventional Nipple-Sparing Mastectomy |
SCIE | 0.2 |
ONCOLOGY SURGERY |
imgenius@yuhs.ac;j.lee@knu.ac.kr; | ||
|
Chae, Yee Soo (Chae, YS) |
Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Hematol & Oncol, Daegu, South Korea Kyungpook Natl Univ, Sch Med, Dept Oncol Hematol, Daegu, South Korea Kyungpook Natl Univ, Dept Oncol Hematol, Chillgok Hosp, Daegu, South Korea Kyungpook Natl Univ, Sch Med, Dept Oncol, Daegu, South Korea Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Oncol, 807 Hoguk Ro, Daegu, South Korea Kyungpook Natl Univ, Kyungpook Natl Univ, Sch Med, Dept Oncol Hematol,Chilgok Hosp, Daegu, South Korea Kyungpook Natl Univ, Chilgok Hosp, Hoguk Ro 807, Daegu 41404, South Korea Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea Kyungpook Natl Univ Chilgok Hosp, Kyungpook Natl Univ, Sch Med, Dept Hematol Oncol, Daegu, South Korea Kyungpook Natl Univ Hosp, Daegu, South Korea Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Daegu, South Korea |
|
|
[JCR상위 1.7] Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer [JCR상위 36.0] Feasibility of an indocyanine green-hyaluronic acid mixture (LuminoMark™) for targeting suspicious axillary lymph nodes in patients with breast cancer [JCR상위 57.2] Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer [JCR상위 1.7] Uncovering of NRAGE/JNK and PI3K/AKT pathways through serial WGS of patients with breast cancer [JCR상위 11.5] Effectiveness of Carboplatin-Prescreening Intradermal Skin Tests to Reduce Unanticipated Immediate Hypersensitivity Reactions: A Comparative Study [JCR상위 44.0] Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer [JCR상위 65.0] Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer [JCR상위 1.7] Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. [JCR상위 18.2] Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study [JCR상위 0.3] Inhibition of lysine acetyltransferase KAT6 in ER⁺HER2⁻ metastatic breast cancer: a phase 1 trial [JCR상위 1.7] A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. [JCR상위 0.3] Inhibition of lysine acetyltransferase KAT6 in ER⁺HER2⁻ metastatic breast cancer: a phase 1 trial (vol 30, pg 2242, 2024) [JCR상위 5.6] Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers |
SCIE | 0.3 |
ONCOLOGY ONCOLOGY;PHARMACOLOGY & PHARMACY ALLERGY;IMMUNOLOGY CELL BIOLOGY OBSTETRICS & GYNECOLOGY;ONCOLOGY BIOCHEMISTRY & MOLECULAR BIOLOGY;CELL BIOLOGY;MEDICINE, RESEARCH & EXPERIMENTAL MEDICINE, GENERAL & INTERNAL |
phy123@knu.ac.kr; dghong@knu.ac.kr;yschae@knu.ac.kr; yschae@knu.ac.kr;hann33@gmail.com; yschae@knu.ac.kr; jjh01@knu.ac.kr; tsurutaj@med.showa-u.ac.jp; meng.li7@pfizer.com;patricia.lorusso@yale.edu; jasonksa@korea.ac.kr;khpark@korea.ac.kr; |
||
|
Chae, Young Kwang (Chae, YK) |
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA Northwestern Univ, Feinberg Sch Med, Dept Internal Med Hematol & Oncol, 645 N Michigan Ave, Suite 1006, Chicago, IL 60611 USA Northwestern Univ, Feinberg Sch Med, Chicago, IL USA Northwestern Univ, Feinberg Sch Med, Dept Internal Med Hematol & Oncol, 645 N Michigan Ave Suite 1006, Chicago, IL 60611 USA |
|
|
[JCR상위 1.7] Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. [JCR상위 46.8] Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments [JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer [JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) [JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria [JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) [JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study [JCR상위 37.6] Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy |
SCIE | 1.7 |
ONCOLOGY ONCOLOGY;RESPIRATORY SYSTEM |
ychae@nm.org; YCHAE@nm.org; |
||
|
Chan, Stephen (Chan, S) |
Chinese Univ Hong Kong, Sir Yue Kong Pao Ctr Canc, State Key Lab Translat Oncol, Dept Clin Oncol, Hong Kong, Peoples R China Chinese Univ Hong Kong, State Key Lab Translat Oncol, Dept Clin Oncol, Sir Yue Kong Pao Ctr Canc, Hong Kong, Peoples R China |
|
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Chang, Te-Sheng (Chang, TS) |
Chiayi Chang Gung Mem Hosp, Puzy City, Taiwan |
|
|
[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | limys@amc.seoul.kr; | ||
|
Chen, Chi-Yi (Chen, CY) |
Chia Yi Christian Hosp, Chiayi, Taiwan Chia Yi Christian Hosp, Cia Yi, Taiwan |
KVZ-1550-2024 Chen, ChiYi |
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB [JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis |
SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY |
tom.evans@barinthusbio.com; limys@amc.seoul.kr; |
||
|
Chen, Chien-Hung (Chen, CH) |
Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan |
|
|
[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | limys@amc.seoul.kr; | ||
|
Cheng, Pin-Nan (Cheng, PN) |
Natl Cheng Kung Univ Hosp, Tainan, Taiwan |
|
|
[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | limys@amc.seoul.kr; | ||
|
Cheong, Jae-Ho (Cheong, JH) |
Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Surg, Seoul, South Korea |
|
|
[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY | SCIE | 1.7 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Cho, Amy (Cho, A) |
|
|
[JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer [JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) [JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria [JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) [JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study |
SCIE | 1.7 | ONCOLOGY | ||||
|
Cho, Eun Kyung (Cho, EK) |
Gachon Univ, Div Med Oncol, Dept Internal Med, Gil Med Ctr, Incheon, South Korea |
|
|
[JCR상위 1.7] A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. | SCIE | 1.7 | ONCOLOGY | |||
|
Cho, Hyun-Woong (Cho, HW) |
|
|
[JCR상위 1.7] Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS) | SCIE | 1.7 | ONCOLOGY | ||||
|
Choi, In Sil (Choi, IS) |
Seoul Natl Univ, Boramae Med Ctr, Seoul, South Korea |
|
|
[JCR상위 1.7] A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. | SCIE | 1.7 | ONCOLOGY | |||
|
Choi, Won-Mook (Choi, WM) |
Asan Med Ctr, Seoul, South Korea Univ Ulsan, Coll Med, Liver Ctr, Asan Med Ctr, Seoul, South Korea |
ABE-2662-2021 Choi, Won-Mook |
|
[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis [JCR상위 3.2] Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007-2021: a nationwide, multicentre, retrospective cohort study |
SCIE | 1.7 |
GASTROENTEROLOGY & HEPATOLOGY MEDICINE, GENERAL & INTERNAL |
limys@amc.seoul.kr; drwon1@snu.ac.kr;hanseungbong@gmail.com;ksukorea@yuhs.ac; |
||
|
Chuang, Wan-Lobg (Chuang, WL) |
Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan |
C-9536-2009 Chuang, Wan-Long |
0000-0002-2376-421X Chuang, Wan-Long |
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; |
페이지 이동: